Astellas is committed to providing timely and accurate information about our business, science and products. This section offers global resources for investors, journalists and media professionals. News and resources from our local affiliates can be viewed in the Local news section. If you are not an investor or journalist, click here.
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
| Su | Mo | Tu | We | Th | Fr | Sa |
|---|---|---|---|---|---|---|
Astellas Pharma Inc. (TSE: 4503; Headquaters: Tokyo; President & CEO: Yoshihiko Hatanaka) and UMN Pharma Inc. (TSE: 4585; Headquaters: Akita; CEO: Tatsuyoshi Hirano) today announced that the...
Tokyo, Japan, October 1, 2013 - Astellas Pharma Inc. (Tokyo: 4503, President and CEO: Yoshihiko Hatanaka, hereinafter called “Astellas”) established today Innovation Management (“AIM”), as...
Astellas Pharma Inc. (“Astellas”; headquarters : Tokyo:4503; President and CEO : Yoshihiko Hatanaka) today announced that a basic agreement has been concluded between Astellas Pharma Tech Co.,...
Tokyo: September 9, 2013 - Toa Eiyo Ltd. (Tokyo; Unlisted; “Toa Eiyo”) and Astellas Pharma Inc. (Tokyo: 4503; “Astellas”) announced today that, on September 10, 2013, Toa Eiyo and Astellas...
TOKYO, September 2, 2013 -- Astellas Pharma Inc. (“Astellas”; Tokyo:4503; President and CEO: Yoshihiko Hatanaka) and MSD K.K. (“MSD” ; President and Representative Director: Tony Alvarez)...
An international public-private partnership (PPP) was launched in July last year to develop a new pediatric formulation to combat schistosomiasis – commonly known as bilharzia – in preschool...
NORTHBROOK, Ill. August 22, 2013 – Astellas Pharma US, Inc. (“Astellas”), a U.S. subsidiary of Tokyo-based Astellas Pharma Inc. (Tokyo: 4503), announced today that ASTAGRAF XLTM (tacrolimus...
Follow us
